Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test
LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development study. In the study, Immunovia’s next-generation test demonstrated specificity of 98 percent and sensitivity of 75 percent in detecting early stage (1 and 2) pancreatic ductal adenocarcinoma (PDAC), a very aggressive and the most common form of pancreatic cancer. The Immunovia test was also